By Leigh Dayton 9 June 2022
It’s official. As of this month, ovarian cancer campaigner Heather Hawkins takes up her role as an Advisory Board Member for Cartherics.
“It’s a privilege and an honour to be part of the Board,” she says. “And I’m looking forward to assisting […]
Chief Development Officer, Dr Nicholas Boyd
Cell therapies have the potential to not only be life-saving but curative for a host of diseases. However, inherent limitations in autologous based CAR-T therapy face major roadblocks for mass adoption and therapeutic effects in solid tumour indications.
On Friday 28 January at 7:30 am AEDT Nicholas will discuss the design, […]
By Leigh Dayton, 17 January 2022
Cellular immunotherapy is revolutionizing cancer treatment, and off-the-shelf or allogeneic, treatments are beginning to replace technologies developed individually for each patient.
This is good news because the potential of allogeneic therapies is great. They promise to significantly save time and cut costs compared […]
By Leigh Dayton, 4 January 2022
When Cartherics Biomedical Honours student Elizabeth (Liz) Bakaniozos opened an e-mail this month from the Director and CEO of Monash University’s Hudson Institute of Medical Research she was “really surprised and grateful”.
And rightly so. Elizabeth Hartland wrote to advise and congratulate Liz on winning the Hudson Institute Lois Salamonsen Honours […]
By Leigh Dayton, 6 December 2021
When eight Cartherics women first teamed-up to walk or run 4km every day in November and raise funds to support women living with ovarian cancer, they set what they believed were achievable goals. The newly minted CARTeam would collectively move 120 km and raise $500.
They sorely misjudged their efforts. Despite […]
By Leigh Dayton 22 November 2021
It was a challenge that had to be met. “This November, walk or run 4km every day and raise funds to support women living with ovarian cancer,” proposed Ovarian Cancer Australia (OCA), a not-for-profit organisation which supports women […]
‘Off-the-Shelf’ Immunotherapy: Manufacture of CD8+ T Cells Derived from Hematopoietic Stem Cells
Cellular immunotherapy is revolutionizing cancer treatment. However, treatments created from each patient’s cells are complex, costly, and limited by the number and quality of killer T cells that can be isolated from and expanded for re-infusion into each patient.
In this […]
By Leigh Dayton
7 October 2021
According to Cartherics CEO Alan Trounson, taking ideas from the laboratory to the marketplace is a “long and tortuous process”. First-hand experience goes far towards identifying and navigating the hurdles of research translation.
And experience – from pioneering work in IVF and embryonic stem cell science […]
By Leigh Dayton
9 August 2021
Cartherics is pleased to announce that CEO Alan Trounson has been congratulated by the National Library of Australia for his recognition on this year’s Queen’s Birthday Honours List.
In recognition of his “distinguished service to medical science, and to in vitro fertilisation and stem cell technologies” Trounson was appointed an […]
By Leigh Dayton
22 July 2021
Cartherics is delighted to announce that it is a sponsor of the Australia and New Zealand Society of Cell and Developmental Biology’s Victorian State Conference. The highly regarded one-day event is booked for 26 August at the University of Melbourne.
Cartherics CEO Alan Trounson welcomes the opportunity to support the meeting.
“It is […]
Cartherics’ mission is the development of novel, immune cell therapy products for the treatment of cancer, endometriosis and Alzheimer’s disease.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
